RxDoctor Payments Data

Stephanie McCrery, MD

Family Medicine · Pinehurst, NCNPI 1134355977

Payments from drug & device makers

$3,523in general payments, 2019–2025

Across 193 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$489
  • Merck$317
  • Bayer$287
  • Lilly USA, LLC$281
  • Daiichi Sankyo Inc.$208
  • AbbVie$206
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$3,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,523 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$183,654
Medicare patients
370
Services billed
6,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$179,328
JardianceEmpagliflozin93$95,872
JanuviaSitagliptin Phosphate79$78,510
FarxigaDapagliflozin Propanediol57$53,059
EliquisApixaban53$51,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$35,973
XareltoRivaroxaban19$30,047
RybelsusSemaglutide13$26,787
MounjaroTirzepatide21$23,868
WegovySemaglutide14$23,396
EntrestoSacubitril/Valsartan19$20,392
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$13,142
GemtesaVibegron16$12,693
Repatha SyringeEvolocumab11$11,615
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$489$229,512161 claims
Boehringer IngelheimJardiance$195$95,87293 claims
MerckJanuvia$317$78,51079 claims
AstraZenecaFarxiga, Breztri Aerosphere$202$63,11173 claims
PfizerEliquis, Paxlovid$96$57,32166 claims
GSKTrelegy Ellipta$154$35,97325 claims
Lilly USA, LLCMounjaro$281$23,86821 claims
AbbVieLinzess, Synthroid, Armour Thyroid$206$9,10959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →